Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

151 to 175 of 324 results

Draft guidance from NICE recommends Bayer's Xarelto for PE and DVT

19-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) this morning (April 19)…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData

17-04-2013

Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

New Zealand considers listing of Neulastim and Actemra

12-04-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…

ActemraAnti-Arthritics/RheumaticsAsia-PacificBiotechnologyNeulastimOncologyPharmaceuticalPricingRegulationRoche

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis

05-04-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

NICE denies NHS use of Pfizer's Inlyta for patients with terminal kidney cancer

28-03-2013

In a second disappointment from the agency this week, US drugs behemoth Pfizer (NYSE: PFE) Ltd expressed…

EuropeInlytaOncologyPfizerPharmaceuticalPricingRegulation

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga

25-03-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

UK's NICE draft guidance says "no" to Roche's Avastin for ovarian cancer

25-03-2013

New, draft guidance issued today (March 25) by the UK's drugs watchdog the National Institute for Health…

AvastinOncologyPharmaceuticalPricingRegulationRoche

Germany's IQWiG finds no proof of added benefit for Bayer's Eylea

22-03-2013

There was disappointment for German drug major Bayer (BAYN: DE), when the German Institute for Quality…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

NICE issues negative draft decision for Novartis' Afinitor

21-03-2013

The UK's National Institute for Health and Clinical Excellence (NICE) today (March 21) issued an Appraisal…

AfinitorEuropeNovartisOncologyPharmaceuticalPricingRegulation

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

The solution for Spanish pharma companies lies abroad

13-03-2013

The pressure on the prices of medicines by Spanish government has seen the pharmaceutical market in Spain…

AlmirallEuropeFinancialGrifolsPharmaceuticalPricingRegulationZeltia

Unnecessary drug regulations hiking Rx prices in USA: NCPA Study

08-03-2013

As drug coverage increases as a result of expanded health insurance and Medicaid coverage under the USA's…

BiotechnologyNorth AmericaPharmaceuticalPricingRegulation

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

UK's NICE backs use of Novartis' Lucentis for diabetic macular edema

27-02-2013

Reversing an earlier negative opinion, in a final guidance issued today (February 27), the UK drugs watchdog…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance

22-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

UK's NICE says no to Novartis' Jakavi for myelofibrosis in draft guidance

13-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (February…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

MEPS vote for access to cheaper generics drugs in Europe; mixed industry reaction

07-02-2013

European patients should have quicker access to cheaper "generic" medicines, according to Members of…

EuropeGenericsLegalPharmaceuticalPricingRegulation

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

UK treatment decisions seriously flawed and must not be used in Europe, say researchers

24-01-2013

The Quality Adjusted Life Years (QALY) approach to deciding what medical treatments are available on…

BiotechnologyEuropePharmaceuticalPricingRegulation

151 to 175 of 324 results

Back to top